[go: up one dir, main page]

ID19290A - Turunan-turunan propiofenon dan proses pembuatannya - Google Patents

Turunan-turunan propiofenon dan proses pembuatannya

Info

Publication number
ID19290A
ID19290A IDP973965A ID973965A ID19290A ID 19290 A ID19290 A ID 19290A ID P973965 A IDP973965 A ID P973965A ID 973965 A ID973965 A ID 973965A ID 19290 A ID19290 A ID 19290A
Authority
ID
Indonesia
Prior art keywords
propiofenon
decreases
making
propiofenon decreases
Prior art date
Application number
IDP973965A
Other languages
English (en)
Inventor
Kenji Tsujihara
Kunio Saito
Mitsuya Hongu
Mamoru Matsumoto
Akira Oku
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of ID19290A publication Critical patent/ID19290A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDP973965A 1996-12-26 1997-12-23 Turunan-turunan propiofenon dan proses pembuatannya ID19290A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34740696 1996-12-26

Publications (1)

Publication Number Publication Date
ID19290A true ID19290A (id) 1998-07-02

Family

ID=18390010

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP973965A ID19290A (id) 1996-12-26 1997-12-23 Turunan-turunan propiofenon dan proses pembuatannya

Country Status (23)

Country Link
US (1) US6048842A (id)
EP (1) EP0850948B1 (id)
KR (1) KR100407029B1 (id)
CN (1) CN1094942C (id)
AR (1) AR010385A1 (id)
AT (1) ATE216704T1 (id)
AU (1) AU719726B2 (id)
BG (1) BG63546B1 (id)
BR (1) BR9706471B1 (id)
CA (1) CA2225439C (id)
DE (1) DE69712172T2 (id)
DK (1) DK0850948T3 (id)
ES (1) ES2176600T3 (id)
HK (1) HK1014960A1 (id)
HU (1) HU228514B1 (id)
ID (1) ID19290A (id)
IL (1) IL122666A (id)
MY (1) MY119350A (id)
NO (1) NO311804B1 (id)
PT (1) PT850948E (id)
RU (1) RU2156247C2 (id)
TW (1) TW406086B (id)
ZA (1) ZA9711560B (id)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ATE455785T1 (de) 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1381361B1 (en) * 2001-04-04 2009-02-25 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
JP4424203B2 (ja) * 2002-04-26 2010-03-03 味の素株式会社 糖尿病予防・治療剤
PL372865A1 (en) * 2002-08-09 2005-08-08 Taisho Pharmaceutical Co, Ltd. Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP1680414A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
WO2005012243A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
CA2534024C (en) * 2003-08-01 2009-06-02 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
AR048377A1 (es) * 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
WO2005012318A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
BRPI0711949A2 (pt) 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
MX2008016231A (es) 2006-06-29 2009-01-16 Taisho Pharma Co Ltd Compuesto de c-fenil 1-tioglucitol.
US7993687B2 (en) * 2006-07-12 2011-08-09 Julianne Marie Kawa Compositions and methods for management of diabetes
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
RS56990B1 (sr) * 2007-09-10 2018-05-31 Janssen Pharmaceutica Nv Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
WO2009143020A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EA022186B1 (ru) 2009-07-10 2015-11-30 Янссен Фармацевтика Нв СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
EP2298782A1 (en) * 2009-08-26 2011-03-23 Sanofi-Aventis Method for producing pyrazole glycoside derivatives
RS55909B1 (sr) * 2009-10-14 2017-09-29 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EA022365B1 (ru) 2010-05-11 2015-12-30 Янссен Фармацевтика Нв Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
ES2586846T3 (es) 2011-04-13 2016-10-19 Janssen Pharmaceutica, N.V. Proceso de preparación de compuestos útiles como inhibidores de SGLT2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US20160033480A1 (en) * 2013-12-16 2016-02-04 Amy Huimeei Lo Immunovir and Components, Immunovir A, B, C, D Utility and Useful Processes
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN104478956A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104497068A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含三氟甲氧基苯s-葡萄糖苷结构的化合物及其用途
CN104497071A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和腈基苯o-葡萄糖苷结构化合物及用途
CN104497069A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一类胺基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104478961A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 含丙烯腈和胺基苯o-葡萄糖苷结构衍生物、其制备方法和用途
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN107827753A (zh) * 2017-11-14 2018-03-23 湖北工业大学 一种对甲基二乙酰氧基碘苯的制备方法
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
JP2025503136A (ja) 2022-01-26 2025-01-30 アストラゼネカ・アクチエボラーグ 前糖尿病の治療又は２型糖尿病の発症リスクを低減する際に使用するためのダパグリフロジン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984394A (en) * 1971-05-14 1976-10-05 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US4031260A (en) * 1971-05-14 1977-06-21 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
US5110801A (en) * 1984-08-13 1992-05-05 Leveen Harry H Treatment of acne
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
US4665058A (en) * 1985-03-16 1987-05-12 The University Of Kentucky Research Foundation Compositions and method of treatment for sickle cell anemia
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2847696B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法

Also Published As

Publication number Publication date
CN1190097A (zh) 1998-08-12
AR010385A1 (es) 2000-06-07
ES2176600T3 (es) 2002-12-01
MY119350A (en) 2005-05-31
KR100407029B1 (ko) 2004-03-30
BG63546B1 (bg) 2002-04-30
PT850948E (pt) 2002-08-30
DK0850948T3 (da) 2002-07-29
BG102148A (en) 1998-09-30
BR9706471B1 (pt) 2012-09-04
TW406086B (en) 2000-09-21
HK1014960A1 (en) 1999-10-08
EP0850948B1 (en) 2002-04-24
ZA9711560B (en) 1998-06-24
IL122666A (en) 2000-06-01
DE69712172T2 (de) 2002-10-31
KR19980064710A (ko) 1998-10-07
AU719726B2 (en) 2000-05-18
NO976072L (no) 1998-06-29
HUP9702534A3 (en) 1999-01-28
EP0850948A1 (en) 1998-07-01
HU9702534D0 (en) 1998-03-02
NO976072D0 (no) 1997-12-23
CA2225439A1 (en) 1998-06-26
DE69712172D1 (de) 2002-05-29
CA2225439C (en) 2005-06-07
AU4841697A (en) 1998-07-02
RU2156247C2 (ru) 2000-09-20
BR9706471A (pt) 1999-05-18
HUP9702534A2 (hu) 1998-07-28
CN1094942C (zh) 2002-11-27
ATE216704T1 (de) 2002-05-15
IL122666A0 (en) 1998-08-16
NO311804B1 (no) 2002-01-28
HU228514B1 (hu) 2013-03-28
US6048842A (en) 2000-04-11

Similar Documents

Publication Publication Date Title
ID19290A (id) Turunan-turunan propiofenon dan proses pembuatannya
ID15947A (id) Senyawa fenol dan proses pembuatannya
ID18494A (id) Turunan pirazola leburan dan proses pembuatannya
ID17307A (id) Komposisi oral dan proses pembuatannya.
ID27859A (id) Tampon dan metoda pembuatannya
ID23684A (id) Komposisi-polimer-organoclay dan pembuatannya
ID16930A (id) Peralatan fotovoltaik dan proses untuk produksinya
ID26172A (id) Proses pembuatan surfaktan-surfaktan alkilbenzenasulfonat dan produk-produknya
ID22821A (id) Turunan sulfonamida, proses pembuatannya dan penggunaannya sebagai obat
ID23985A (id) Baterai dan metode pembuatannya
ID16862A (id) Komposisi-komposisi elastomer dan metoda-metoda pembuatannya
ID23557A (id) Poliester baru dan proses pembuatan poliester
ID21233A (id) Sepatu dan metoda pembuatannya
ID19385A (id) Adesif termosetting dan metoda pembuatannya
ID17800A (id) Bahan-bahan pengatur secara internal dan metoda pembuatannya
ID22782A (id) Perenggang baterai dan metoda pembuatannya
ID15992A (id) Papan lamina dan proses pembuatannya
ID27275A (id) Intermediet dan proses untuk pembuatan olanzapin
ID18244A (id) Komposisi polipropilena dan metoda pembuatannya dan katalis untuk
ID16923A (id) Komposisi-komposisi bitumen dan proses pembuatannya
ID26902A (id) Proses dan radas untuk pembuatan melamina
ID23304A (id) Turunan-turunan diaza-spiro [3,5] nonana, proses pembuatan dan penggunaannya
ID18860A (id) Katalis hidrocracking distilat dan proses pembuatannya
ID24173A (id) 1,2,3,4,5,6 heksahidro-2-6-metano-3-benzazosin-10-ol, proses pembuatan dan penggunannya untuk obat-obatan
ID15861A (id) Instalasi dan proses metalurgi mengandung fero